Drug Trial Radar · NCT03216564
An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
320
Planned (sponsor's estimate)
Start
May 10, 2017
Primary completion
May 10, 2019
Study completion May 10, 2019
Sponsor
- Lead sponsor
- Hamad Medical CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Weill Cornell Medical College in Qatar
- First posted
- Jul 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetic kidney disease (nephropathy) develops in nearly 40% of patients with type 2 diabetes mellitus. Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys due to uncontrolled blood sugar levels, which mean that the kidneys become less effective at filtering urine. This is associated with albuminuria (protein in the urine). Treatment with some drugs reduces the loss of albumin through the urine and delays disease progression. There is increasing evidence that vitamin D could also be important in management of diabetic kidney disease. The aim of this study is to investigate the efficacy and safety of a combined regimen of calcitriol (active vitamin D) and established drugs for diabetic kidney disease.
Conditions
- Diabetic Nephropathies
Interventions
CalcitriolDrug
Active vitamin D (Calcitriol) 0.25 micrograms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary albumin creatinine ratio (ACR) measured biochemicallyTime frame: 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hamad Medical Corporation
Doha, Qatar · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.